The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Agenus; Amgen; Bristol-Myers Squibb; MSD; Pfizer; Roche; Ryvu Therapeutics
Consulting or Advisory Role - Roche
Research Funding - Agenus
Travel, Accommodations, Expenses - Novartis; Roche
 
Honoraria - Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Day One Therapeutics; Janssen; Novartis; Roche; SK Life Sciences
Research Funding - BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Janssen Research & Development (Inst); MSD (Inst); Pharmacyclics (Inst); PreComb Therapeutics (Inst); Syndax (Inst)
Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results.
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Immunomedics; Janssen; Janssen (Inst); Loxo/Lilly; MSD Oncology; MSD Oncology (Inst); Pfizer/EMD Serono; Roche; Seagen; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Martin H. Schuler
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Novartis
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; Novartis; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)
 
Gopa Iyer
Consulting or Advisory Role - Basilea; Bayer; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Speakers' Bureau - Gilead Sciences; Lynx Group
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Olaf Witt
No Relationships to Disclose
 
Toshihiko Doi
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Oncolys BioPharma; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Daiichi Sankyo; Janssen; Kyowa Hakko Kirin; MSD; Otsuka; Rakuten Medical; Sumitomo Dainippon; Takeda
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); IQvia (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Avvinity; Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; Inspirna; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Seagen; Servier; Sotio; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc
Other Relationship - Imedex; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource
 
David A. Reardon
Honoraria - Advantagene; Agenus; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Deciphera; DelMar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kintara Therapeutics; KIYATEC; Medicenna; Merck; Merck KGaA; NEUVOGEN; Novocure; Oncorus; Regeneron; Sumitono Dainippon Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Vivacitas Oncology; Y-mAbs Therapeutics
Consulting or Advisory Role - Advantagene; Agenus; Agios; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Delmar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Kintara Therapeutics; Kiyatec; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Taiho Pharmaceutical; Vivacitas Oncology
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Enterome (Inst); Incyte (Inst); Omniox
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Debiopharm Group; Genentech; Ipsen; MedImmune; MSD; Novartis; Orion; Pfizer; Roche; Sanofi
Research Funding - Abbvie; Aduro Biotech; Agios; Amgen; arGEN-X BVBA; AstraZeneca; AVEO; Bayer; BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; EOS Pharmaceuticals; Exelixis; Forma Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; Gortec; H3 Biomedicine; Incyte; Innate Pharma; Janssen; Kura Oncology; Kyowa Kirin Pharmaceutical Development; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merus; MSD; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Oncopeptides; Orion; Pfizer; PharmaMar; Pierre Fabre; Roche; Sanofi; SERVIER; Sierra Oncology; Taiho Oncology; Takeda; Tesaro; The Lymphoma Academic Research Organization; Xencor
 
Daniel Palmer
Consulting or Advisory Role - AstraZeneca; Boston Scientific; Bristol-Myers Squibb; Eisai; Ipsen; MSD; Roche; Sirtex Medical; Viatris
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; Nucana; Sirtex Medical
 
Iwona Lugowska
No Relationships to Disclose
 
Jermaine Coward
Research Funding - AstraZeneca (Inst)
 
Marcelo Corassa
No Relationships to Disclose
 
Kim Stuyckens
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Huimin Liao
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
Honoraria - Janssen Research & Development
Travel, Accommodations, Expenses - Janssen Research & Development
 
Saltanat Najmi
Employment - Amgen; Johnson & Johnson; Tmunity Therapeutics, Inc.
Stock and Other Ownership Interests - Amgen
 
Constance Hammond
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Ademi E. Santiago-Walker
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Hussein Sweiti
Employment - Janssen Research & Development
 
Shubham Pant
Honoraria - 4D Pharma
Consulting or Advisory Role - Ipsen; Xencor; Zymeworks
Research Funding - 4D Pharma (Inst); Arcus Biosciences (Inst); ArQule (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Onco Response (Inst); Purple Biotech (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst)